WO2024079276A1 - Photolytically degradable compounds and methods for synthesising thereof - Google Patents
Photolytically degradable compounds and methods for synthesising thereof Download PDFInfo
- Publication number
- WO2024079276A1 WO2024079276A1 PCT/EP2023/078379 EP2023078379W WO2024079276A1 WO 2024079276 A1 WO2024079276 A1 WO 2024079276A1 EP 2023078379 W EP2023078379 W EP 2023078379W WO 2024079276 A1 WO2024079276 A1 WO 2024079276A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- formula
- photolytically
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 149
- 238000000034 method Methods 0.000 title claims abstract description 70
- 125000003118 aryl group Chemical group 0.000 claims abstract description 33
- 238000006467 substitution reaction Methods 0.000 claims abstract description 18
- 239000000376 reactant Substances 0.000 claims abstract description 14
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 12
- 239000000575 pesticide Substances 0.000 claims abstract description 12
- 125000000160 oxazolidinyl group Chemical group 0.000 claims abstract description 8
- 230000003115 biocidal effect Effects 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 241000972773 Aulopiformes Species 0.000 claims description 23
- 241001674048 Phthiraptera Species 0.000 claims description 23
- 235000019515 salmon Nutrition 0.000 claims description 23
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical class ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 10
- 241000251468 Actinopterygii Species 0.000 claims description 9
- 235000019688 fish Nutrition 0.000 claims description 9
- 101100006370 Arabidopsis thaliana CHX2 gene Proteins 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000005938 Teflubenzuron Substances 0.000 claims description 6
- 229960005091 chloramphenicol Drugs 0.000 claims description 6
- 230000003467 diminishing effect Effects 0.000 claims description 6
- CJDWRQLODFKPEL-UHFFFAOYSA-N teflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC(Cl)=C(F)C(Cl)=C1F CJDWRQLODFKPEL-UHFFFAOYSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 239000005893 Diflubenzuron Substances 0.000 claims description 5
- 241001247234 Lepeophtheirus salmonis Species 0.000 claims description 5
- 241000607479 Yersinia pestis Species 0.000 claims description 5
- 150000001336 alkenes Chemical class 0.000 claims description 5
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- 229960003405 ciprofloxacin Drugs 0.000 claims description 5
- 229940019503 diflubenzuron Drugs 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 150000001345 alkine derivatives Chemical class 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 3
- 230000000361 pesticidal effect Effects 0.000 claims description 3
- 239000005912 Lufenuron Substances 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 125000001743 benzylic group Chemical group 0.000 claims description 2
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960000521 lufenuron Drugs 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- QQQYTWIFVNKMRW-UHFFFAOYSA-N diflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C=C1 QQQYTWIFVNKMRW-UHFFFAOYSA-N 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 abstract description 2
- 238000010506 ionic fission reaction Methods 0.000 abstract 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 25
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 14
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 12
- -1 antibacterials Chemical class 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- 238000006303 photolysis reaction Methods 0.000 description 10
- 229940125782 compound 2 Drugs 0.000 description 8
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- 230000015843 photosynthesis, light reaction Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000005102 attenuated total reflection Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 150000002917 oxazolidines Chemical class 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XUNYDVLIZWUPAW-UHFFFAOYSA-N (4-chlorophenyl) n-(4-methylphenyl)sulfonylcarbamate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)OC1=CC=C(Cl)C=C1 XUNYDVLIZWUPAW-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 4
- 238000009360 aquaculture Methods 0.000 description 4
- 244000144974 aquaculture Species 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 3
- 241000193985 Streptococcus agalactiae Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 230000000590 parasiticidal effect Effects 0.000 description 3
- 239000002297 parasiticide Substances 0.000 description 3
- 238000010916 retrosynthetic analysis Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 3
- 239000002351 wastewater Substances 0.000 description 3
- 238000004293 19F NMR spectroscopy Methods 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000006416 CBr Chemical group BrC* 0.000 description 2
- 102000005469 Chitin Synthase Human genes 0.000 description 2
- 108700040089 Chitin synthases Proteins 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241000277263 Salmo Species 0.000 description 2
- 241000316146 Salmo trutta trutta Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- PSAZZGAKKTZUGJ-UHFFFAOYSA-N [O-][N+](C(C=C1)=CC=C1NCC(CC1=CC=CC=C1)O)=O Chemical compound [O-][N+](C(C=C1)=CC=C1NCC(CC1=CC=CC=C1)O)=O PSAZZGAKKTZUGJ-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 208000028454 lice infestation Diseases 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000004065 wastewater treatment Methods 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000495778 Escherichia faecalis Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241000965040 Galatheidae Species 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- 241000238073 Homarus gammarus Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 231100000703 Maximum Residue Limit Toxicity 0.000 description 1
- 241000133262 Nauplius Species 0.000 description 1
- 241000239246 Nephrops norvegicus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000277289 Salmo salar Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000610375 Sparisoma viride Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- XVIYETJYQZZMJS-UHFFFAOYSA-N [O-][N+](C1=CC=C(CC(CNC(C=C(C(OC(C(C(F)(F)F)F)(F)F)=C2)Cl)=C2Cl)O)C=C1)=O Chemical compound [O-][N+](C1=CC=C(CC(CNC(C=C(C(OC(C(C(F)(F)F)F)(F)F)=C2)Cl)=C2Cl)O)C=C1)=O XVIYETJYQZZMJS-UHFFFAOYSA-N 0.000 description 1
- DGKKIKVUIZRDQG-UHFFFAOYSA-N [O-][N+](C1=CC=C(CC(CNC2=CC=CC=C2)O)C=C1)=O Chemical compound [O-][N+](C1=CC=C(CC(CNC2=CC=CC=C2)O)C=C1)=O DGKKIKVUIZRDQG-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- VBCVPMMZEGZULK-NRFANRHFSA-N indoxacarb Chemical compound C([C@@]1(OC2)C(=O)OC)C3=CC(Cl)=CC=C3C1=NN2C(=O)N(C(=O)OC)C1=CC=C(OC(F)(F)F)C=C1 VBCVPMMZEGZULK-NRFANRHFSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- QGLVEAGMVUQOJP-UHFFFAOYSA-N prop-2-enylboronic acid Chemical compound OB(O)CC=C QGLVEAGMVUQOJP-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/76—1,3-Oxazoles; Hydrogenated 1,3-oxazoles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P7/00—Arthropodicides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P7/00—Arthropodicides
- A01P7/04—Insecticides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/10—Modification of an amino radical directly attached in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
Definitions
- the present invention relates to the field of organic chemistry and more specifically to a method of designing and preparing biologically active compounds, which undergo degradation easily in the environment. More specifically, the invention relates to strategic design of compounds that have a biological function of interest as well as to a functionality which enables subsequent photolytic decomposition under ambient conditions.
- the invention provides photolytically degradable compounds which may be used e. g. as parasiticides, pesticides, antimicrobial compounds, such as antibacterials, including antibiotics, and afterwards easily incapacitated by exposure to light.
- Multi-drug resistant (MDR) bacteria are a widespread problem and several public-health organisations have described the situation as a crisis that would have catastrophic consequences.
- Alarming data from around the world have shown that over 100 pharmaceutical compounds have been detected in drinking water, wastewater, ground water and aquatic organisms.
- One example of the above pharmaceutical compounds is the antibiotic ciprofloxacin that has been detected in wastewater across the world.
- Conventional UV treatment of effluent water containing ciprofloxacin has been carried out but proved to have no effect.
- Another example of such compounds is the broad-spectrum antibiotic chloramphenicol.
- Phosphopyricin is an antimicrobial compound with a photosensitive chemical architecture that reduces its accumulation in the environment.
- Said invention alleviates at least part of the above-discussed problems and at least partially addresses one or more of the above-mentioned needs.
- a method for synthesising a photolytically degradable compound comprising: a) defining a biologically active compound which analogue is to be synthesised, wherein the biologically active compound comprises at least one aromatic group, the aromatic group being substituted, b) providing a reactant molecule comprising the at least one aromatic group, and c) synthesising a photolytically degradable compound by introducing in the reactant molecule at least one nitro substitution in said at least one aromatic group and introducing an oxazolidine group, wherein the photolytically degradable compound is defined by Formula I:
- Formula I wherein at least one of A, B, C and D is selected from a group consisting of H, Cl, Br, B(OH) 2 , CN, CH 2 NR 1 R 2 and [CH 2 NR 1 R 2 R 3 ] + , wherein each of R 1 , R 2 and R 3 is selected from a group consisting of H, branched or unbranched C-i-Ce alkyl, and
- R 1 independently selected from a group consisting of H, F, Cl, I, Br, CN, CF 3 , CI-C 6 alkyl, alkoxy with a Ci-C 6 alkyl, NH 2 , NHR 1 , NR 1 R 2 and [NR 1 R 2 R 3 ] + , where R 1 , R 2 and R 3 are as defined above, and
- n is 0-4
- Z is one selected from a group consisting of H, aryl, and NHC(O)R 7 , wherein R 7 is selected from a group consisting of R 5 , wherein R 5 is branched or unbranched Ci-C 3 alkyl,
- X is at least one selected from a group consisting of F, Cl, alkyne and
- K is H and L is as defined above, or
- K is H and L is CH2OR 4 , wherein R 4 is selected from a group consisting of H and branched or unbranched C-i-Ce alkyl, Q is one selected from a group consisting
- a method for managing water resources is provided, more specifically by utilising the photolytically degradable compounds obtained by the method according to the first aspect of the invention in treatment of water, the water containing at least one selected from a group consisting of microorganisms and pests.
- a method for at least reducing a population of salmon lice is provided, more specifically by utilising the photolytically degradable compounds obtained by the method according to the first aspect of the invention.
- the photolytically degradable compound obtained by the method according to the first aspect of the invention is provided for use in at least reducing or controlling the size of a population of salmon lice.
- a method for at least diminishing direct or indirect damage salmon lice causes to fish is provided, more specifically by utilising the photolytically degradable compounds obtained by the method according to the first aspect of the invention.
- the photolytically degradable compound obtained by the method according to the first aspect of the invention is provided for use in at least diminishing direct or indirect damage salmon lice causes to fish.
- Figure 1 1 H-NMR spectra before and after photolysis of compound 2.
- Figure 2 UV-Vis spectra of compounds 2, 2a, 2b and 2c, respectively.
- Figure 3 1 H-NMR spectra before and after photolysis of compound 2a.
- a photolytically degradable compound includes one or more photolytically degradable compound
- a molecule includes one or more molecules and the like.
- biologically active compound is understood within the scope of the invention to refer to a compound which may be capable of at least one selected from a group consisting of inhibiting the growth of organisms, interfering with normal functioning of organisms, destroying organisms and the like.
- light is understood within the scope of the invention to refer to what is commonly known as “daylight” or light used in an artificial and/or closed environment corresponding to “daylight”; the light may comprise light of a specific wavelength or a range of wavelengths.
- an analogue is understood within the scope of the invention to refer to what is commonly known a structural analogue or a chemical analogue; i. e. an analogue of compound A is a compound in which one or more individual atoms have been replaced with either an atom or a functional group, the atom and the functional group being different from that in compound A.
- a method for synthesising a photolytically degradable compound comprising: a) defining a biologically active compound which analogue is to be synthesised, wherein the biologically active compound comprises at least one aromatic group, the aromatic group being substituted, b) providing a reactant molecule comprising the at least one aromatic group, and c) synthesising a photolytically degradable compound by introducing in the reactant molecule at least one nitro substitution in said at least one aromatic group and introducing an oxazolidine group, wherein the photolytically degradable compound is defined by Formula I:
- Formula I wherein at least one of A, B, C and D is selected from a group consisting of H, Cl, Br, B(OH) 2 , CN, CH 2 NR 1 R 2 and [CH 2 NR 1 R 2 R 3 ] + , wherein each of R 1 , R 2 and R 3 is selected from a group consisting of H, branched or unbranched C-i-Ce alkyl, and
- R 1 independently selected from a group consisting of H, F, Cl, I, Br, CN, CF 3 , CI-C 6 alkyl, alkoxy with a Ci-C 6 alkyl, NH 2 , NHR 1 , NR 1 R 2 and [NR 1 R 2 R 3 ] + , where R 1 , R 2 and R 3 are as defined above, and
- n is 0-4
- Z is one selected from a group consisting of H, aryl, and NHC(O)R 7 , wherein R 7 is selected from a group consisting of R 5 , wherein R 5 is branched or unbranched Ci-C 3 alkyl,
- X is at least one selected from a group consisting of F, Cl, alkyne and
- K is H and L is as defined above, or
- K is H and L is CH2OR 4 , wherein R 4 is selected from a group consisting of H and branched or unbranched C-i-Ce alkyl,
- K and L may be in any spatial orientation and hence various stereoisomers may be envisaged according to the present invention.
- the wording “defining a biologically active compound which analogue is to be synthesised” implies that a user of the present method decides which biologically active compound to use as a target compound in the method of the present invention.
- the synthesising may include a selective synthesis.
- the biologically active compound may be selected from a group consisting of antimicrobial compounds and pesticidal compounds.
- the person skilled in the art can determine in view of a relevant biologically active compound, i. e. in this case the biologically active compound which analogue is to be synthesised, the most advantageous parameters for the synthesis according to the first aspect of the invention, such as necessary amounts and concentrations of reagents and appropriate reaction conditions, including temperatures at which the steps of the synthesis process are to be conducted and duration of the steps thereof.
- the present method may be performed at room temperature.
- temperatures higher than the room temperature temperatures above about 30 °C, above about 40 °C, above about 50 °C, above about 60 °C may be chosen.
- the step c) of the method may include first synthesising a photolytically degradable compound by introducing at least one nitro substitution in said at least one aromatic group of the reactant molecule and then introducing an oxazolidine group.
- introducing at least one nitro substitution in said at least one aromatic group of the reactant molecule may lead to formation of a first photolytically degradable compound
- the following introducing an oxazolidine group in the first photolytically degradable compound may lead to formation of a second photolytically degradable compound.
- the at least one nitro substitution in said at least one aromatic group of the reactant molecule may be at least one selected from a group consisting of a metanitro substitution, a para-nitro substitution and an ortho-nitro substitution.
- said at least one aromatic group of the reactant molecule may have both a para-nitro substitution and a meta-nitro substitution.
- the photolytically degradable compound may be defined by Formula I A:
- R 1 independently selected from a group consisting of H, F, Cl, I, Br, CN, CF 3 , CI-C 6 alkyl, alkoxy with a Ci-C 6 alkyl, NH 2 , NHR 1 , NR 1 R 2 and [NR 1 R 2 R 3 ] + , where R 1 , R 2 and R 3 are as defined above, and
- n is 0-4
- Z is one selected from a group consisting of H, aryl and NHC(O)R 7 , wherein R 7 is selected from a group consisting of R 5 , a monohalogenated derivative thereof and perhalogenated derivative thereof, wherein R 5 is branched or unbranched Ci-C 3 alkyl, and wherein
- Formula IV K is H and L is as defined above, or
- K is H and L is CH2OR 4 , wherein R 4 is selected from a group consisting of H and branched or unbranched C-i-Ce alkyl.
- the photolytically degradable compound may comprise more than one aromatic group.
- the substituent Z in Formula I may be aryl as defined by Formula II:
- each of the substituents E, F, G and H may be as defined above for the substituents A, B, C and D.
- the nitro group may be in meta-, ortho- or paraposition to the carbon attaching Z to the carbon chain of the photolytically degradable compound.
- Z may be beta lactam.
- the substituents A, B, C, D, L, K and H may be same.
- K may be same as L, wherein L may be branched or unbranched C-i-Ce alkyl, branched or unbranched C1-C3, and C1-C2 alkyl.
- K may be H and L may be CH2CH2OR or CH2CH2CH2OR, wherein R one selected from a group consisting of H, and branched or unbranched C-i-Ce alkyl.
- the photolytically degradable compound obtained by the above method may be as defined by Formula V:
- this is the photolytically degradable compound, wherein Q is H and K is
- the idea concerning photolytic decomposition has been extended to antibiotics as wastewater treatment plants do not have the necessary design to completely remove the antibiotics from the water.
- ciprofloxacin has been detected in the effluent from a treatment plant, and another study investigated commonly used antibiotics in the U.S. and showed that even though the concentration of the antibiotics decreased during wastewater treatment they remain in the water.
- Another antibiotic that causes similar issues is chloramphenicol.
- the method according to the first aspect of the invention allows for synthesis of a compound with a functionality similar to that of chloramphenicol.
- the photolytically degradable compound may be chloramphenicol analogue as depicted by Formula VI A.
- One or more Cl may be substituted with F.
- photolytically degradable compounds obtained according to the above method are provided.
- the photolytically degradable compound may be a chloramphenicol analogue as one selected from those depicted by Formula VI C:
- the photolytically degradable compound may have one substituent selected from A, B, C, D, K, L and Z and have its ethanolamine-based compound-precursor defined by Formula VII a: In this case the photolytically degradable compound will be defined by Formula VII:
- the photolytically degradable compound according to the invention may be one or more selected from a group consisting of compounds 2, 2a, 2b, 3, 4, 5, 6, 7, 8, 9 and 10 (Table 1 ).
- At least one benzylic C-C bond of said photolytically degradable compound may be heterolytically cleaved by exposure to light at basic pH in aqueous environment.
- Said basic pH may be between about 7 and about 13, between about 7 and about 11 , between about 7 and 8.
- the present invention relates to synthesis of photolytically degradable compounds resembling other biologically active compounds, for example antimicrobial compounds, such as antibiotics, and pesticides, which can undergo degradation by exposure to light.
- antimicrobial compounds such as antibiotics, and pesticides
- the biologically active compound which analogue is to be synthesised may have at least one biological activity selected from a group consisting of an antimicrobial activity and a pesticidal activity.
- the biologically active compound which analogue is to be synthesised may be an antibiotic, e. g. ciprofloxacin, chloramphenicol or penicillin.
- the biologically active compound which analogue is to be synthesised may be a pesticide, e. g. diflubenzuron, teflubenzuron or lufenuron.
- the photolytically degradable compound synthesised according to the first aspect of the invention may have a biological activity substantially similar to that of its non- photolytically degradable analogue, i. e. the biological activity may be at least 80 %, at least 90 % or at least 99 % of that of the non-photolytically degradable analogue.
- the chemical structure of the photolytically degradable compound may be defined by retrosynthetic analysis.
- the retrosynthetic analysis involves subjecting a target structure, in this case the biologically active compound which analogue is to be synthesised, to a deconstruction process, which corresponds to the reverse of a synthetic reaction.
- the retrosynthetic analysis includes providing a reactant compound and then devising a path to convert it to the target compound, e. g. identifying an immediate precursor that can be converted to the target compound using a known reaction.
- a method for managing water resources is provided, more specifically by utilising the photolytically degradable compounds provided by the present invention in treatment of water; the water may contain microorganisms as well as pests.
- the water may be wastewater.
- the water may be drinking water.
- the pH of the water may be adjusted as appropriate for example to be between about 7 and about 13, between about 7 and about 11 , between about 7 and about 8.
- a method for at least reducing the size of a population of salmon lice (Lepeophtheirus salmonis) is provided, more specifically by utilising the photolytically degradable compounds provided by the present invention.
- the photolytically degradable compound obtained by the method according to the first aspect of the invention is provided for use in at least reducing or controlling the size of a population of salmon lice.
- a pesticide or a parasiticide obtained and synthesised according to the method of the invention may be used to treat salmon in aquaculture or open water to reduce the number of or eliminate salmon lice.
- the water containing the pesticide may be subjected to light to cause photolytic degradation of any remaining pesticide.
- the pH of the water may be adjusted as appropriate, for example to be between about 7 and about 13, between about 7 and about 11 , between about 7 and about 8. The person skilled in the art will appreciate that pH conditions may be adjusted depending on the pesticide or parasiticide used.
- a method for at least diminishing direct or indirect damage salmon lice causes to fish is provided, more specifically by utilising the photolytically degradable compounds provided by the present invention.
- the photolytically degradable compound obtained by the method according to the first aspect of the invention is provided for use in at least diminishing direct or indirect damage salmon lice causes to fish.
- the fish may be selected from a group consisting of salmon, trout and the like.
- Figure 1 shows the 1 H-NMR spectra before and after photolysis of compound 2 (see Table 1 above).
- the y-axis shows relative intensity, and the X-axis shows [ppm]. From bottom to top, the spectra are obtained before and after photolysis, respectively.
- the key CH2-oxazolidine group signals are highlighted in grey. Full decomposition of compound 2 at pH 8 was observed after 2 h.
- Figure 2 shows UV-Vis spectra of compounds 2, 2a, 2b and 2c, respectively.
- the y-axis shows absorbance A (mAU), and x-axis shows wavelength A (nm).
- Compounds 2, 2a, 2b and 2c had a max of 304 nm, 414 nm, 291 nm and 466 nm, respectively.
- Figure 3 shows 1 H-NMR spectra before and after photolysis of compound 2a (see Table 1 above). From bottom to top, the spectra are obtained before and after photolysis, respectively. The y-axis shows relative intensity, and the X-axis shows [ppm]. Full decomposition of compound 2a at pH 8 was observed after two hours.
- a final product of the synthesis was obtained by first introducing at least one nitro substitution in at least one aromatic group of a reactant molecule to obtain a first photolytically degradable compound and then introducing an oxazolidine group in the first photolytically degradable compound to obtain the final product of the synthesis.
- the first photolytically degradable compound i. e. an aminol (compound 1 ) was prepared using the procedure described below (Scheme 1 ).
- Scheme 1 a Suzuki- Miyaura cross-coupling reaction with allyl boronic acid pinacol ester was used according to a method described by Kotha and co-workers (Kotha, S.; Behera, M.; Shah, V., A. Synlett 2005, 12, 1877-1880).
- Subsequent treatment with mCPBA gave the corresponding epoxide.
- a Lewis acid-promoted epoxide ring-opening reaction using 5 M lithium perchlorate-diethyl ether (LPDE) solution provided compound 1.
- Scheme 1 Synthesis of compound 1. Reagents and conditions: (i) 1 ) Pd(PPh 3 ) 4 , CsF, AllyIBpin, THF, reflux, 2) mCPBA, DCM, rt; (ii) 5 M LPDE, 40 °C; (iii) H2SO4, HNO 3 , 0 °C
- UV-Vis analysis showed that the four compounds 2, 2a, 2b and 2c had a max of 304 nm, 414 nm, 291 nm and 466 nm, respectively ( Figure 2).
- This biological activity may result in death of pests containing a chitin exoskeleton. This includes pests on land and in water.
- Salmon lice Lepeophtheirus salmonis
- All lice used for testing belongs to an established lice strain (LsGulen) and all information of breeding and maintenance of the lice is outlined by Hamre et al. (Parasitol. Int. 2009, 58, 451 -460).
- IR spectra were recorded on an Agilent Cary 630 FT-IR spectrophotometer equipped with an attenuated total reflectance (ATR) attachment. Samples were analysed neat on a ZnSe crystal, and the absorption frequencies are given in wave numbers (cm -1 ).
- UV-Vis spectra were obtained on an Agilent 8453 single-beam UV-Vis spectrophotometer with a deuterium-discharge lamp for the UV range and a tungsten lamp for the visible wavelength range. Samples were analysed in an Agilent open-top UV quartz cell (10 mm, 3.0 mL) with ethanol as solvent. Wavelengths are reported in nm, and molar attenuation coefficients in M’ 1 crrr 1 .
- NMR spectra were recorded on a Broker AscendTM 400 spectrometer (400.13 MHz for 1 H, 100.61 MHz for 13 C, 376.46 MHz for 19 F) or a Broker AscendTM 850 spectrometer (850.13 MHz for 1 H and 213.77 MHz for 13 C).
- Coupling constants (J) are given in Hz and the multiplicity is reported as singlet (s), doublet (d), triplet (t), sextet (sxt), multiplet (m) and broad singlet (bs).
- TLC Thin-layer chromatography
- silica gel 60 F254
- solvent systems consisting of various mixtures of petroleum ether, ethyl acetate and DCM. Staining was achieved with either exposure to UV light (254 and/or 365 nm) or a potassium permanganate stain. Flash chromatography was performed with a hand pump and 230-400 mesh silica gel.
- Formaldehyde (0.137 mL, 4.0 eq., 1 .84 mmol) and formic acid (0.019 mL, 1.1 eq., 0.51 mmol) in 1 ,2-dichloroethane (9.2 mL, 0.05 M) were added to a solution of 1- ((2-bromo-4-(trifluoromethoxy)phenyl)amino)-3-(4-nitrophenyl)propan-2-ol (0.2 g, 1.0 eq., 0.46 mmol). The resulting mixture was stirred at room temperature for 2 days. The crude product was diluted with water (20 mL), and the aqueous layer was extracted using CH2CI2 (40 mL x 3).
- Formaldehyde (0.139 mL, 4.0 eq., 1 .88 mmol) and formic acid (0.020 mL, 1.1 eq., 0.52 mmol) in 1 ,2-dichloroethane (9.4 mL, 0.05 M) were added to a solution of 1 - ((6-bromo-2,3,4-trifluorophenyl)amino)-3-(4-nitrophenyl)propan-2-ol (0.19 g, 1.0 eq., 0.47 mmol). The resulting mixture was stirred at room temperature for 2 days.
- the crude product was diluted with water (20 mL), and the aqueous layer was extracted using CH2CI2 (40 mL x 3). The combined organic layers were washed with water (20 mL), brine, dried over MgSC and concentrated under reduced pressure.
- the crude was purified by silica-gel column chromatography (pet. ether/EtOAc + 3% EtsN, PE 100-60:40-50:50-45:55-40:60-50:50, Rf. 0.70) to provide the title compound (81.6 mg, 42%) as a colourless oil.
- Vmax 3092 (C-H, alkene), 2921 (C-H, alkane), 1900 (C-H, aromatic), 1594 (N-O, nitro), 1303-1264 (C-O-C), 802 (C-CI);
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Insects & Arthropods (AREA)
- Oncology (AREA)
- Agronomy & Crop Science (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dentistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The present invention relates to a method for synthesising a photolytically degradable compound, the method comprising defining a biologically active compound which analogue is to be synthesised, wherein the biologically active compound comprises at least one aromatic group, the aromatic group being substituted, providing a reactant molecule comprising the at least one aromatic group and synthesising a photolytically degradable compound by introducing in the reactant molecule at least one nitro substitution in said at least one aromatic group and introducing an oxazolidine group. The biologically active compound may be an antimicrobial compound, such as an antibiotic or a pesticide. The photolytically degradable compound may be capable of heterolytic cleavage when exposed to light at basic pH in aqueous environment.
Description
PHOTOLYTICALLY DEGRADABLE COMPOUNDS AND METHODS FOR SYNTHESISING THEREOF
TECHNICAL FIELD
The present invention relates to the field of organic chemistry and more specifically to a method of designing and preparing biologically active compounds, which undergo degradation easily in the environment. More specifically, the invention relates to strategic design of compounds that have a biological function of interest as well as to a functionality which enables subsequent photolytic decomposition under ambient conditions. Thus, the invention provides photolytically degradable compounds which may be used e. g. as parasiticides, pesticides, antimicrobial compounds, such as antibacterials, including antibiotics, and afterwards easily incapacitated by exposure to light.
BACKGROUND
An excessive use of antibiotics both in the human health care sector and agriculture leads to emergence of drug-resistant bacteria strains. Multi-drug resistant (MDR) bacteria are a widespread problem and several public-health organisations have described the situation as a crisis that would have catastrophic consequences. Alarming data from around the world have shown that over 100 pharmaceutical compounds have been detected in drinking water, wastewater, ground water and aquatic organisms. One example of the above pharmaceutical compounds is the antibiotic ciprofloxacin that has been detected in wastewater across the world. Conventional UV treatment of effluent water containing ciprofloxacin has been carried out but proved to have no effect. Another example of such compounds is the broad-spectrum antibiotic chloramphenicol.
To counteract further growth of MDR bacteria, it is necessary to develop antibiotics based on scaffolds with a structural motif that will enable their degradation under ambient conditions so that accumulation in the biosphere does not take place. Since most antibiotics act inside the body, conceivable new agents must be stable under aqueous and in particular physiological conditions.
Furthermore, the aquaculture industry is a large global business, which is estimated to continue growing. In Norway aquaculture products are the largest export commodity after oil and gas, and therefore it important to alleviate problems
associated with production of the aquaculture products. One such problem is presence of salmon lice (Lepeophtheirus salmonis), which may induce epizootics in wild fish while feeding on its skin, mucus and blood. Since the salmon farms commonly use open-net pens, such lice infestations can easily move to adjacent farms and may also infect the local populations of fish, such as sea trout (Salmo trutta) and wild Atlantic salmon (Salmo salar).
In order to address the problems related to the salmon lice infestation, large quantities of pesticides, such as diflubenzuron and teflubenzuron (see below), are currently being applied. These compounds act as chitin synthase inhibitors preventing the salmon lice from forming the chitin-rich exoskeleton after moulting and ultimately leading to their death. However, there are many studies that show that the above compounds are stable with a half-life of 170 days. These compounds have been detected in water as far away as 1100 m from pens and have proven to exhibit negative impacts on king crab, shrimp, squat lobster, and European and Norway lobster. The detected levels of teflubenzuron were sufficient to induce mortality in salmon lice during the developmental stages when salmon lice lack exoskeleton.
Additionally, the maximum-residue limit for these pesticides for saithe and the above-mentioned crustaceans, respectively, exceeded that for Atlantic salmon. Therefore, the above discussion also directly concerns food safety. Thus, there is an urgent need to generate chitin synthase inhibitors that have a shorter half-life.
Diflubenzuron Teflubenzuron
Light-degradable compounds which decompose in the environment, such as phosphopyricin, have been described in e. g. CA2972079. Phosphopyricin is an antimicrobial compound with a photosensitive chemical architecture that reduces its accumulation in the environment.
Despite that there is still a need to protect the environment from harmful biologically active compounds by designing new strategies directed to creating efficient ways of reducing amount of or eliminating residues of pharmaceutical
compounds and other harmful biologically active compounds in all aqueous compartments.
SUMMARY OF THE INVENTION
In the light of the above, it is an object of the present invention to provide a method for synthesising photolytically degradable compounds as well as photolytically degradable compounds and methods of utilising said compounds for managing water resources, reducing a population of salmon lice and diminishing direct or indirect damage salmon lice causes to fish.
Said invention alleviates at least part of the above-discussed problems and at least partially addresses one or more of the above-mentioned needs.
According to a first aspect of the invention a method is provided for synthesising a photolytically degradable compound, more precisely the method comprising: a) defining a biologically active compound which analogue is to be synthesised, wherein the biologically active compound comprises at least one aromatic group, the aromatic group being substituted, b) providing a reactant molecule comprising the at least one aromatic group, and c) synthesising a photolytically degradable compound by introducing in the reactant molecule at least one nitro substitution in said at least one aromatic group and introducing an oxazolidine group, wherein the photolytically degradable compound is defined by Formula I:
Formula I wherein at least one of A, B, C and D is selected from a group consisting of H, Cl, Br, B(OH)2, CN, CH2NR1R2 and [CH2NR1R2R3]+, wherein each of R1, R2 and R3 is selected from a group consisting of H, branched or
unbranched C-i-Ce alkyl, and
O(CH2)o(CX2)p(CH2)q(CHX)r(CH2)s(CX2)t(CH2)u(CX3)v(CHX2)w(CH2X)x(C H3)y, where o = 0-5, p = 0-5, q = 0-5, r = 0-5, s = 0-4, t = 0-4, u = 0-4, v = 0-1 , w = 0-1 , x = 0-1 , y = 0-1 , provided that only one of v, w, x and y is 1 , while the other three of v, w, x and y are 0, and where X is selected from a group consisting of F and Cl, while each of the other three of A, B, C and D is
1 ) independently selected from a group consisting of H, F, Cl, I, Br, CN, CF3, CI-C6 alkyl, alkoxy with a Ci-C6 alkyl, NH2, NHR1, NR1R2 and [NR1R2R3]+, where R1, R2 and R3 are as defined above, and
2) is attached to any carbon atom available for substitution in the phenyl group, n is 0-4,
Z is one selected from a group consisting of H, aryl, and NHC(O)R7, wherein R7 is selected from a group consisting of R5, wherein R5 is branched or unbranched Ci-C3 alkyl,
and derivatives thereof comprising one or more selected from a group consisting of F and Cl, and wherein
K is same as L, wherein L is selected from a group consisting of H, branched or unbranched C1 -C6 alkyl, alkene and (CH2)o(CX2)p(CH2)q(CHX)r(CH2)s(CX2)t(CH2)u(CX3)v(CHX2)w(CH2X)x(CH3 )y, wherein o = 0-5, p = 0-5, q = 0-5, r = 0-5, s = 0-4, t = 0-4, u = 0-4, v = 0-1 , w = 0-1 , x = 0-1 , y = 0-1 , provided that only one of v, w, x, and y is
1 , while each of the other three of v, w, x, and y is 0, and wherein X is at least one selected from a group consisting of F, Cl, alkyne and
K is H and L is as defined above, or
K is H and L is CH2OR4, wherein R4 is selected from a group consisting of H and branched or unbranched C-i-Ce alkyl,
Q is one selected from a group consisting
According to further aspects of the invention photolytically degradable compounds obtained according to the above method are provided. More specifically, chloramphenicol analogues depicted by Formula VI C, wherein n = 0 or 1 :
Chloramphenicol analogues and
Formula VII
According to another aspect of the invention a method for managing water resources is provided, more specifically by utilising the photolytically degradable compounds obtained by the method according to the first aspect of the invention in treatment of water, the water containing at least one selected from a group consisting of microorganisms and pests.
According to another aspect of the invention a method for at least reducing a population of salmon lice (Lepeophtheirus salmonis) is provided, more specifically by utilising the photolytically degradable compounds obtained by the method according to the first aspect of the invention. Alternatively, the photolytically degradable
compound obtained by the method according to the first aspect of the invention is provided for use in at least reducing or controlling the size of a population of salmon lice.
According to yet another aspect of the invention a method for at least diminishing direct or indirect damage salmon lice causes to fish is provided, more specifically by utilising the photolytically degradable compounds obtained by the method according to the first aspect of the invention. Alternatively, the photolytically degradable compound obtained by the method according to the first aspect of the invention is provided for use in at least diminishing direct or indirect damage salmon lice causes to fish.
These and other aspects of the invention are apparent from and elucidated with reference to the embodiments described hereinafter.
BRIEF DESCRIPTION OF THE DRAWINGS
For exemplifying purposes, the invention will be described in closer detail in the following with reference to embodiments thereof illustrated in the attached drawings, wherein:
Figure 1 : 1H-NMR spectra before and after photolysis of compound 2.
Figure 2: UV-Vis spectra of compounds 2, 2a, 2b and 2c, respectively.
Figure 3: 1H-NMR spectra before and after photolysis of compound 2a.
DETAILED DESCRIPTION OF INVENTION
In the following detailed description the technical terms and expressions are defined, and embodiments of the invention are described.
Generally, all terms and expressions used in the application text are to be interpreted according to the meaning commonly applied to them in the pertinent prior art unless explicitly defined otherwise herein.
As used in this specification and the appended claims, the singular forms ”a”, ”an” and ’’the” include plural referents unless the context clearly dictates otherwise. Thus, e. g. ”a photolytically degradable compound” includes one or more photolytically degradable compound, “a molecule” includes one or more molecules and the like.
The term “biologically active compound” is understood within the scope of the invention to refer to a compound which may be capable of at least one selected from
a group consisting of inhibiting the growth of organisms, interfering with normal functioning of organisms, destroying organisms and the like.
The term “light” is understood within the scope of the invention to refer to what is commonly known as “daylight” or light used in an artificial and/or closed environment corresponding to “daylight”; the light may comprise light of a specific wavelength or a range of wavelengths.
The term “analogue” is understood within the scope of the invention to refer to what is commonly known a structural analogue or a chemical analogue; i. e. an analogue of compound A is a compound in which one or more individual atoms have been replaced with either an atom or a functional group, the atom and the functional group being different from that in compound A.
Illustrative embodiments of the invention are described below.
According to a first aspect of the invention a method is provided for synthesising a photolytically degradable compound, the method comprising: a) defining a biologically active compound which analogue is to be synthesised, wherein the biologically active compound comprises at least one aromatic group, the aromatic group being substituted, b) providing a reactant molecule comprising the at least one aromatic group, and c) synthesising a photolytically degradable compound by introducing in the reactant molecule at least one nitro substitution in said at least one aromatic group and introducing an oxazolidine group, wherein the photolytically degradable compound is defined by Formula I:
Formula I wherein at least one of A, B, C and D is selected from a group consisting of H, Cl, Br, B(OH)2, CN, CH2NR1R2 and [CH2NR1R2R3]+, wherein each of R1, R2 and R3 is selected from a group consisting of H, branched or
unbranched C-i-Ce alkyl, and
O(CH2)o(CX2)p(CH2)q(CHX)r(CH2)s(CX2)t(CH2)u(CX3)v(CHX2)w(CH2X)x(C H3)y, where o = 0-5, p = 0-5, q = 0-5, r = 0-5, s = 0-4, t = 0-4, u = 0-4, v = 0-1 , w = 0-1 , x = 0-1 , y = 0-1 , provided that only one of v, w, x and y is 1 , while the other three of v, w, x and y are 0, and where X is selected from a group consisting of F and Cl, while each of the other three of A, B, C and D is
1 ) independently selected from a group consisting of H, F, Cl, I, Br, CN, CF3, CI-C6 alkyl, alkoxy with a Ci-C6 alkyl, NH2, NHR1, NR1R2 and [NR1R2R3]+, where R1, R2 and R3 are as defined above, and
2) is attached to any carbon atom available for substitution in the phenyl group, n is 0-4,
Z is one selected from a group consisting of H, aryl, and NHC(O)R7, wherein R7 is selected from a group consisting of R5, wherein R5 is branched or unbranched Ci-C3 alkyl,
and derivatives thereof comprising one or more selected from a group consisting of F and Cl, and wherein
K is same as L, wherein L is selected from a group consisting of H, branched or unbranched C1 -C6 alkyl, alkene and (CH2)o(CX2)p(CH2)q(CHX)r(CH2)s(CX2)t(CH2)u(CX3)v(CHX2)w(CH2X)x(CH3 )y, wherein o = 0-5, p = 0-5, q = 0-5, r = 0-5, s = 0-4, t = 0-4, u = 0-4, v = 0-1 , w = 0-1 , x = 0-1 , y = 0-1 , provided that only one of v, w, x, and y is
1 , while each of the other three of v, w, x, and y is 0, and wherein X is at least one selected from a group consisting of F, Cl, alkyne and
K is H and L is as defined above, or
K is H and L is CH2OR4, wherein R4 is selected from a group consisting of H and branched or unbranched C-i-Ce alkyl,
According to further aspects of the invention photolytically degradable compounds obtained according to the above method are provided. More specifically, chloramphenicol analogues depicted by Formula VI C, wherein n = 0 or 1 :
Chloramphenicol analogues
Formula VII
It is appreciated that a person skilled in the art realises that K and L may be in any spatial orientation and hence various stereoisomers may be envisaged according to the present invention.
The wording “defining a biologically active compound which analogue is to be synthesised” implies that a user of the present method decides which biologically active compound to use as a target compound in the method of the present invention.
The synthesising may include a selective synthesis.
The biologically active compound may be selected from a group consisting of antimicrobial compounds and pesticidal compounds.
It is appreciated that the person skilled in the art can determine in view of a relevant biologically active compound, i. e. in this case the biologically active
compound which analogue is to be synthesised, the most advantageous parameters for the synthesis according to the first aspect of the invention, such as necessary amounts and concentrations of reagents and appropriate reaction conditions, including temperatures at which the steps of the synthesis process are to be conducted and duration of the steps thereof. For example, the present method may be performed at room temperature. For synthesising some photolytically degradable compounds, temperatures higher than the room temperature, temperatures above about 30 °C, above about 40 °C, above about 50 °C, above about 60 °C may be chosen.
The step c) of the method may include first synthesising a photolytically degradable compound by introducing at least one nitro substitution in said at least one aromatic group of the reactant molecule and then introducing an oxazolidine group. In this case introducing at least one nitro substitution in said at least one aromatic group of the reactant molecule may lead to formation of a first photolytically degradable compound, whereas the following introducing an oxazolidine group in the first photolytically degradable compound may lead to formation of a second photolytically degradable compound.
The at least one nitro substitution in said at least one aromatic group of the reactant molecule may be at least one selected from a group consisting of a metanitro substitution, a para-nitro substitution and an ortho-nitro substitution. Advantageously said at least one aromatic group of the reactant molecule may have both a para-nitro substitution and a meta-nitro substitution.
Formula I A wherein at least one of A, B, C and D is selected from a group consisting of B(OH)2, CN, CH2NR1R2 and [CH2NR1R2R3]+, wherein each of R1, R2 and R3 is
selected from a group consisting of H, branched or unbranched C-i-Ce alkyl, and O(CH2)o(CX2)p(CH2)q(CHX)r(CH2)s(CX2)t(CH2)u(CX3)v(CHX2)w(CH2X)x(C H3)y, where o = 0-5, p = 0-5, q = 0-5, r = 0-5, s = 0-4, t = 0-4, u = 0-4, v = 0-1 , w = 0-1 , x = 0-1 , y = 0-1 , provided that only one of v, w, x and y is 1 , while the other three of v, w, x and y are 0, and where X is selected from a group consisting of F and Cl, while each of the other three of A, B, C and D is
1 ) independently selected from a group consisting of H, F, Cl, I, Br, CN, CF3, CI-C6 alkyl, alkoxy with a Ci-C6 alkyl, NH2, NHR1, NR1R2 and [NR1R2R3]+, where R1, R2 and R3 are as defined above, and
2) is attached to any carbon atom available for substitution in the phenyl group, n is 0-4,
Z is one selected from a group consisting of H, aryl and NHC(O)R7, wherein R7 is selected from a group consisting of R5, a monohalogenated derivative thereof and perhalogenated derivative thereof, wherein R5 is branched or unbranched Ci-C3 alkyl, and wherein
K is same as L, wherein L is selected from a group consisting of H, branched or unbranched C1 -C6 alkyl, alkene and (CH2)o(CX2)p(CH2)q(CHX)r(CH2)s(CX2)t(CH2)u(CX3)v(CHX2)w(CH2X)x(CH3 )y, wherein o = 0-5, p = 0-5, q = 0-5, r = 0-5, s = 0-4, t = 0-4, u = 0-4, v = 0-1 , w = 0-1 , x = 0-1 , y = 0-1 , provided that only one of v, w, x, and y is 1 , while each of the other three of v, w, x and y is 0, and wherein X is one selected from a group consisting of F, Cl, alkyne and
Formula IV
K is H and L is as defined above, or
K is H and L is CH2OR4, wherein R4 is selected from a group consisting of H and branched or unbranched C-i-Ce alkyl.
The photolytically degradable compound may comprise more than one aromatic group. The substituent Z in Formula I may be aryl as defined by Formula II:
Formula II wherein each of the substituents E, F, G and H may be as defined above for the substituents A, B, C and D. The nitro group may be in meta-, ortho- or paraposition to the carbon attaching Z to the carbon chain of the photolytically degradable compound.
Z may be beta lactam. The photolytically degradable compound, wherein Z is beta lactam, may be defined by either Formula III a or Formula III below, wherein n = 0 or 1.
Formula III a Formula III
The substituents A, B, C, D, L, K and H may be same.
Alternatively, it may be said that this is the photodegradable compound, wherein A, B, C, D, L, K and H are same
The substituents K and L in Formula I may have various forms.
K may be same as L, wherein L may be branched or unbranched C-i-Ce alkyl, branched or unbranched C1-C3, and C1-C2 alkyl.
K may be H and L may be CH2CH2OR or CH2CH2CH2OR, wherein R one selected from a group consisting of H, and branched or unbranched C-i-Ce alkyl.
Formula V
Alternatively, it may be said that this is the photolytically degradable
compound, wherein Q is H and K is
The person skilled in the art will appreciate that as the advantages of the present invention are closely related to the chemical structure of the compounds, there may be any organic compound that fulfils the structural criteria presented herein. Non-limiting examples of such organic compounds are a pesticide, exemplified by diflubenzuron or teflubenzuron, and an antibiotic, exemplified by chloramphenicol.
The idea concerning photolytic decomposition has been extended to antibiotics as wastewater treatment plants do not have the necessary design to completely remove the antibiotics from the water. For example, ciprofloxacin has been detected in the effluent from a treatment plant, and another study investigated commonly used antibiotics in the U.S. and showed that even though the concentration of the antibiotics decreased during wastewater treatment they remain in the water. Another antibiotic that causes similar issues is chloramphenicol.
The method according to the first aspect of the invention allows for synthesis of a compound with a functionality similar to that of chloramphenicol. The photolytically degradable compound may be chloramphenicol analogue as depicted by Formula VI A.
Formula VI A
The photolytically degradable compound may be a chloramphenicol analogue defined by Formula VI B below, wherein n = 0 or 1 . One or more Cl may be substituted with F.
Formula VI B
According to further aspects of the invention photolytically degradable compounds obtained according to the above method are provided. The photolytically degradable compound may be a chloramphenicol analogue as one selected from those depicted by Formula VI C:
Chloramphenicol analogues
Formula VI C
Additional substitution patterns on the aromatic group may also be envisaged within the scope of the present invention. The photolytically degradable compound
may have one substituent selected from A, B, C, D, K, L and Z and have its ethanolamine-based compound-precursor defined by Formula VII a:
In this case the photolytically degradable compound will be defined by Formula VII:
Formula VII
The photolytically degradable compound according to the invention may be one or more selected from a group consisting of compounds 2, 2a, 2b, 3, 4, 5, 6, 7, 8, 9 and 10 (Table 1 ).
Table 1 . Compounds 2, 2a, 2b and 3
At least one benzylic C-C bond of said photolytically degradable compound may be heterolytically cleaved by exposure to light at basic pH in aqueous environment. Said basic pH may be between about 7 and about 13, between about 7 and about 11 , between about 7 and 8.
In its broadest sense, the present invention relates to synthesis of photolytically degradable compounds resembling other biologically active compounds, for example antimicrobial compounds, such as antibiotics, and pesticides, which can undergo degradation by exposure to light.
The biologically active compound which analogue is to be synthesised may have at least one biological activity selected from a group consisting of an antimicrobial activity and a pesticidal activity. The biologically active compound which analogue is to be synthesised may be an antibiotic, e. g. ciprofloxacin, chloramphenicol or penicillin. The biologically active compound which analogue is to be synthesised may be a pesticide, e. g. diflubenzuron, teflubenzuron or lufenuron. The photolytically degradable compound synthesised according to the first aspect of the invention may have a biological activity substantially similar to that of its non- photolytically degradable analogue, i. e. the biological activity may be at least 80 %, at least 90 % or at least 99 % of that of the non-photolytically degradable analogue.
The chemical structure of the photolytically degradable compound may be defined by retrosynthetic analysis. As the person skilled in the art knows, the retrosynthetic analysis involves subjecting a target structure, in this case the biologically active compound which analogue is to be synthesised, to a deconstruction process, which corresponds to the reverse of a synthetic reaction. The retrosynthetic analysis includes providing a reactant compound and then devising a path to convert it to the target compound, e. g. identifying an immediate precursor that can be converted to the target compound using a known reaction.
According to another aspect of the invention a method for managing water resources is provided, more specifically by utilising the photolytically degradable compounds provided by the present invention in treatment of water; the water may contain microorganisms as well as pests. The water may be wastewater. The water may be drinking water. The pH of the water may be adjusted as appropriate for example to be between about 7 and about 13, between about 7 and about 11 , between about 7 and about 8.
According to another aspect of the invention a method for at least reducing the size of a population of salmon lice (Lepeophtheirus salmonis) is provided, more specifically by utilising the photolytically degradable compounds provided by the present invention. Alternatively, the photolytically degradable compound obtained by the method according to the first aspect of the invention is provided for use in at least reducing or controlling the size of a population of salmon lice. A pesticide or a parasiticide obtained and synthesised according to the method of the invention may be used to treat salmon in aquaculture or open water to reduce the number of or eliminate salmon lice. Following the treatment, the water containing the pesticide may be subjected to light to cause photolytic degradation of any remaining pesticide. The pH of the water may be adjusted as appropriate, for example to be between about 7 and about 13, between about 7 and about 11 , between about 7 and about 8. The person skilled in the art will appreciate that pH conditions may be adjusted depending on the pesticide or parasiticide used.
According to yet another aspect of the invention a method for at least diminishing direct or indirect damage salmon lice causes to fish is provided, more specifically by utilising the photolytically degradable compounds provided by the present invention. Alternatively, the photolytically degradable compound obtained by the method according to the first aspect of the invention is provided for use in at least diminishing direct or indirect damage salmon lice causes to fish. The fish may be selected from a group consisting of salmon, trout and the like.
It is appreciated that the above-mentioned embodiments of the first aspect of the present invention may also apply to the further aspects of the present invention.
The invention has mainly been described above with reference to some embodiments. However, as it is readily appreciated by the person skilled in the art, other embodiments than the ones disclosed above are equally possible within the scope of the invention as defined by the appended claims.
DETAILED DESCRIPTION OF THE DRAWINGS
Figures 1-3 all illustrate results obtained as described in the experimental section below:
Figure 1 shows the 1H-NMR spectra before and after photolysis of compound 2 (see Table 1 above). The y-axis shows relative intensity, and the X-axis shows
[ppm]. From bottom to top, the spectra are obtained before and after photolysis, respectively. The key CH2-oxazolidine group signals are highlighted in grey. Full decomposition of compound 2 at pH 8 was observed after 2 h.
Figure 2 shows UV-Vis spectra of compounds 2, 2a, 2b and 2c, respectively. The y-axis shows absorbance A (mAU), and x-axis shows wavelength A (nm). Compounds 2, 2a, 2b and 2c had a max of 304 nm, 414 nm, 291 nm and 466 nm, respectively.
Figure 3 shows 1H-NMR spectra before and after photolysis of compound 2a (see Table 1 above). From bottom to top, the spectra are obtained before and after photolysis, respectively. The y-axis shows relative intensity, and the X-axis shows [ppm]. Full decomposition of compound 2a at pH 8 was observed after two hours.
Experimental section
The present examples are provided for illustrative purposes only and are not to be construed as limiting the scope of the present invention as defined by the appended claims.
In one embodiment a final product of the synthesis, the final product being a photolytically degradable compound, was obtained by first introducing at least one nitro substitution in at least one aromatic group of a reactant molecule to obtain a first photolytically degradable compound and then introducing an oxazolidine group in the first photolytically degradable compound to obtain the final product of the synthesis.
Results
I. Synthesis of model compounds:
The first photolytically degradable compound, i. e. an aminol (compound 1 ), was prepared using the procedure described below (Scheme 1 ). First, a Suzuki- Miyaura cross-coupling reaction with allyl boronic acid pinacol ester was used according to a method described by Kotha and co-workers (Kotha, S.; Behera, M.; Shah, V., A. Synlett 2005, 12, 1877-1880). Subsequent treatment with mCPBA gave the corresponding epoxide. A Lewis acid-promoted epoxide ring-opening reaction using 5 M lithium perchlorate-diethyl ether (LPDE) solution provided compound 1.
Scheme 1 : Synthesis of compound 1. Reagents and conditions: (i) 1 ) Pd(PPh3)4, CsF, AllyIBpin, THF, reflux, 2) mCPBA, DCM, rt; (ii) 5 M LPDE, 40 °C; (iii) H2SO4, HNO3, 0 °C
The final product of the synthesis (compound 2) was prepared from the corresponding ethanolamine-based compound (compound 1 ) by treating the latter with formaldehyde and formic acid in DCE at room temperature (Scheme 2).
Scheme 2. Formation of oxazolidine analogue 2 from ethanolamine 1
Using the same procedure as above, the appropriate ethanolamines could be converted into the corresponding oxazolidines in yields ranging from 88-91 % (Scheme 3).
Scheme 3. Synthesis of model compounds containing the oxazolidine group By replacing formaldehyde with acetaldehyde in the reaction with ethanolamine it was possible to obtain the methyl substituted oxazolidine 2c in 90% yield (Scheme 4).
Scheme 4. Formation of methyl substituted oxazolidine 2c
II. Photolysis:
Subjecting compound 2 to photodecomposition in MeCN/water (7:3) at pH 8 resulted in full decomposition after two hours (Figure 1 ). The same treatment of the precursor compound (compound 1 ) resulted in full decomposition only after 24 h. Thus, compound 2 decomposed 12 times faster under light (laboratory conditions) than the corresponding ethanolamine-based compound 1.
Subjecting oxazolidine 2a to photodecomposition in MeCN/water (7:3) at pH 8 resulted in full decomposition after two hours (Figure 3).
UV-Vis analysis showed that the four compounds 2, 2a, 2b and 2c had a max of 304 nm, 414 nm, 291 nm and 466 nm, respectively (Figure 2).
III. Biological activity:
Compounds 2 and 12 were tested against both Gram-positive and Gramnegative bacteria, including E. faecalis, E. coli, P. aeruginosa, S. aureus, S. agalactiae and S. epidermidis. For S. agalactiae compound 2 showed a minimum inhibitory concentration of 25 pM, whereas its precursor compound (compound 1 ) showed a minimum inhibitory concentration of 6.3 pM. For S. agalactiae compound 12 showed a minimum inhibitory concentration of 75 pM, whereas its precursor compound (corresponding ethanolamine-based compound) showed a minimum inhibitory concentration of 12.5 pM.
The following tests can be conducted to evaluate the above-mentioned compounds for chitin synthetase inhibitor properties. This biological activity may result in death of pests containing a chitin exoskeleton. This includes pests on land and in water. Salmon lice (Lepeophtheirus salmonis) is used as a model organism for testing of chitin synthetase activity.
All lice used for testing belongs to an established lice strain (LsGulen) and all information of breeding and maintenance of the lice is outlined by Hamre et al. (Parasitol. Int. 2009, 58, 451 -460).
General procedure for testing with the live-dead assay as follows. 5-30 nauplius I stage of the salmon lice are exposed for 1 h at 10 °C at concentrations 1 .0 ppt and 0.1 ppt according. The lice are subsequently transferred to incubators with a constant flow of seawater at 9 °C. After 7 days the number of surviving nauplii or copepodids are counted and their condition is subjectively evaluated.
Compounds that show activity in the live-dead assay and the corresponding photodecomposition mixtures are dissolved in DMSO to a concentration of 39-40 ppt. These samples are then diluted with seawater to a concentration of 0.1 ppt, 0.01 ppt, 0.001 ppt and 0.0001 ppt. Diflubenzurone samples prepared by the same method as described for the oxazolidines are used as positive control and DMSO (40 ppt) is used as negative control. All solutions are tested using the live-dead assay described above. An active compound would prevent formation of the exoskeleton when nauplii develop resulting in observation of dead nauplii and no copepodids.
Description of the general procedure for synthesis of model compounds
An appropriate aldehyde (4 equiv.) and formic acid (1.1 equiv.) in 1 ,2- dichloroethane (DCE) were added to a solution of amino alcohol (1 .0 equiv.). The resulting reaction mixture was then stirred under an argon at room temperature until completion of the reaction as determined by TLC analysis. The crude mixture was diluted by addition of water (5 mL) and the aq. layer was extracted using CH2CI2 (3 x 5 mL). The combined organic layers were washed with water (1 x 5 mL) and brine (1 x 5 mL), dried (MgSC ), filtered and evaporated onto celite and purified by silica gel column chromatography using the eluents as indicated. The below procedure provides the target compounds (Scheme 5).
Scheme 5: Synthesis of oxazolidine resembling compound
Description of spectral analysis
IR spectra were recorded on an Agilent Cary 630 FT-IR spectrophotometer equipped with an attenuated total reflectance (ATR) attachment. Samples were analysed neat on a ZnSe crystal, and the absorption frequencies are given in wave numbers (cm-1).
UV-Vis spectra were obtained on an Agilent 8453 single-beam UV-Vis spectrophotometer with a deuterium-discharge lamp for the UV range and a tungsten lamp for the visible wavelength range. Samples were analysed in an Agilent open-top UV quartz cell (10 mm, 3.0 mL) with ethanol as solvent. Wavelengths are reported in nm, and molar attenuation coefficients in M’1crrr1.
NMR spectra were recorded on a Broker Ascend™ 400 spectrometer (400.13 MHz for 1H, 100.61 MHz for 13C, 376.46 MHz for 19F) or a Broker Ascend™ 850 spectrometer (850.13 MHz for 1H and 213.77 MHz for 13C). Coupling constants (J) are given in Hz and the multiplicity is reported as singlet (s), doublet (d), triplet (t), sextet (sxt), multiplet (m) and broad singlet (bs). The chemical shift values are reported upfield to downfield in ppm, and calibration is done using the residual solvent signals for chloroform-d (1H 7.26 ppm; 13C 77.16 ppm) or acetonitrile-d3 (1H 1 .94 ppm; 13C 1 .32 ppm).27 Calibration for 19F NMR is done using a,a,a- trifluorotoluene as internal standard in chloroform-d (-62.61 ppm) and acetonitrile-d3 (-63.10 ppm). High-resolution mass spectra were obtained on a JEOL AccuTOF™ T100GC mass spectrometer operated in ESI mode. Low-resolution mass spectra were recorded on an Advion expression compact mass spectrometer (CMS) operated in ESI mode equipped with a Plate Express® TLC plate reader for sample injection. A solution of ammonium acetate (3.0 mM) and formic acid (0.05%) in acetonitrile and water (95/5) was used as mobile phase for both positive and negative ESI modes.
Thin-layer chromatography (TLC) was carried out with silica gel (60 F254) on aluminium sheets with solvent systems consisting of various mixtures of petroleum ether, ethyl acetate and DCM. Staining was achieved with either exposure to UV light (254 and/or 365 nm) or a potassium permanganate stain. Flash chromatography was performed with a hand pump and 230-400 mesh silica gel.
Description of the detailed procedure for synthesis of some model compounds and results of spectral analysis thereof
3-(2 , 5-D ich loro~4-( 1 , 1 ,2,3,3,3-hexafluoropropoxy)phenyl)-5-(4-nitrobenzyl)oxazolidine
Following the general procedure, the title compound was prepared from 1- ((2,5-dichloro-4-(1 ,1 , 2,3,3, 3-hexafluoropropoxy)phenyl)amino)-3-(4- nitrophenyl)propan-2-ol (30.0 mg, 0.059 mmol), formaldehyde (37%, 0.020 mL, 0.24 mmol), formic acid (2.4 pL, 0.065 mL) and DCE (2 mL). After a reaction time of 23 hours, workup was carried out according to the general procedure and purification by silica gel column chromatography (pet. ether/CFhCk, 7:3 v/v) and concentration of the relevant fractions [Rf = 0.20 (pet. ether/CFhCk, 7:3 v/v)] gave the target compound as a pale oil (13.0 mg, 43%). Spectral data are presented below.
IR (ATR): Vmax 2931 , 2879, 1599, 1519, 1350, 1198, 1113 cm-1;
1H NMR (400 MHz, CD3CN): 5 8.14 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 8.7 Hz, 2H), 7.40 (t, J = 0.9 Hz, 1 H), 7.04 (s, 1 H), 5.56 (dsxt, J = 42.7 Hz, 5.8 Hz, 1 H), 4.91 (dd, J = 9.0 Hz, 4.8 Hz, 2H), 4.41 -4.35 (m, 1 H), 3.59 (dd, J = 10.2 Hz, 6.2 Hz, 1 H), 3.26 (dd, J = 10.2 Hz, 7.5 Hz, 1 H), 3.11 -3.02 (m, 2H);
13C NMR (100 MHz, CD3CN): 5 147.8, 147.2, 146.5, 138.7, 131.4, 127.4, 126.9, 124.3, 124.2, 123.7, 120.3, 85.4 (dq, JCF = 35.1 Hz), 83.6, 77.9, 55.4, 39.7 (one carbon was obscured or overlapping);
19F NMR (376 MHz, CD3CN): 5 -75.7-75.8 (q, J = 9.5 Hz, 3F), -78.3-78.9 (m, 1 F), -79.6-80.3 (m, 1 F), -213.4-213.5 (m, 1 F);
UV (EtOH): Amax 304 nm.
5-Benzyl-3-(4-nitrophenyl)oxazolidine (Compound 2a):
Following the general procedure, the title compound was prepared from 1 -(4- nitrophenylamino)-3-phenylpropan-2-ol (100.0 mg, 0.37 mmol), formaldehyde (37%, 0.12 mL, 1 .47 mmol), formic acid (1 .5 pL, 0.41 mmol) and DCE (5 mL). After a reaction time of 20 hours, workup was carried out according to the general procedure to give the crude as a bright yellow solid (92.7 mg, 88%), which was essentially pure as shown by NMR, mp 125-127 °C. Spectral data are presented below.
IR (ATR): Vmax 3429, 3078, 2919, 2850, 1596, 908 cm’1;
1H NMR (400 MHz, CDCI3): 6 8.09 (d, J = 9.2 Hz, 2H), 7.33-7.29 (m, 2H), 7.25-7.22 (m, 3H), 6.34 (d, J = 9.2 Hz, 2H), 5.06 (d, J = 3.0 Hz, 1 H), 4.88 (d, J = 2.9 Hz, 1 H), 4.52-4.45 (m, 1 H), 3.50 (dd, J = 8.9 Hz, 6.0 Hz, 1 H), 3.21-3.17 (m, 1 H), 3.12 (dd, J = 13.8 Hz, 6.7 Hz, 1 H), 2.94 (dd, J = 13.8 Hz, 6.5 Hz, 1 H);
13C NMR (100 MHz, CDCI3): 6 149.2, 138.1 , 136.8, 129.2, 128.8, 127.1 , 126.5, 110.7, 80.2, 79.6, 50.5, 39.4;
UV (EtOH): Amax414 nm.
Following the general procedure, the title compound was prepared from 1 -(4- nitrophenyl)-3-(phenylamino)propan-2-ol (110.0 mg, 0.40 mmol), formaldehyde (37%, 0.13 mL, 1 .61 mmol), formic acid (0.02 mL, 0.44 mmol) and DCE (5 mL). After a reaction time of 2 days, workup was carried out according to the general procedure to give the crude as an orange solid (103.9 mg, 91 %), which was essentially pure as shown by NMR, mp 133-135 °C. Spectral data are presented below.
IR (ATR): Vmax 2912, 2832, 2751 , 1596, 1508, 1343, 1176, 855 cm’1;
1H NMR (400 MHz, CDCI3): 6 8.19 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.7 Hz, 2H), 7.25 (dd, J = 8.6 Hz, 7.4 Hz, 2H), 6.79 (tt, J = 8.2 Hz, 0.9 Hz, 1 H), 6.50 (dd, J = 8.7 Hz, 1 .0 Hz, 2H), 5.00 (d, J = 2.1 Hz, 1 H), 4.87 (d, J = 2.2 Hz, 1 H), 4.55-4.48 (m, 1 H), 3.52 (dd, J = 8.4 Hz, 6.1 Hz, 1 H), 3.18-3.13 (m, 2H), 3.08 (dd, J = 14.1 Hz, 5.3 Hz, 1 H); 1
13C NMR (100 MHz, CDCI3): 6 147.1 , 145.5, 145.5, 130.2, 129.5, 123.9, 117.9, 112.6, 81.3, 78.4, 51.1 , 39.7;
UV (EtOH): Amax 291 nm.
Following the general procedure, the title compound was prepared from 1 -(4- nitrophenylamino)-3-phenylpropan-2-ol (100.0 mg, 0.37 mmol), acetaldehyde (0.083 mL, 1 .48 mmol), formic acid (1 .5 pL, 0.41 mmol) and DCE (5 mL). After a reaction time of 20 hours, workup was carried out according to the general procedure to give the crude as a bright yellow solid (99.7 mg, 90%), which was essentially pure as shown by NMR, mp 116-118 °C. Spectral data are presented below.
IR (ATR): Vmax3068, 3026, 2979, 2921 , 2883, 1595, 1481 , 1309, 746 cm’1;
1H NMR (400 MHz, CDCI3): 6 8.14-8.09 (m, 4H), 7.35-7.32 (m, 4H), 7.29-7.24 (m, 6H), 6.45 (d, J = 9.2 Hz, 2Hminor), 6.43 (d, J = 9.4 Hz, 2Hmajor), 5.48 (q, J = 5.4 Hz, 1 H major), 5.35 (q, J = 5.1 Hz, 1 Hminor), 4.72-4.65 (m, 1 H major), 4.35-4.28 (m, 1 Hminor), 3.60-3.53 (m, 2H), 3.39-3.30 (m, 1 H), 3.21 -3.09 (m, 3H), 2.95 (dd, J = 13.8 Hz, 6.7 Hz, 1 H), 2.87 (dd, J = 13.8 Hz, 7.0 Hz, 1 H), 1 .49 (d, J = 5.1 Hz, 3Hminor), 1 .45 (d, J =
5.5 Hz, 3Hmajor);
13C NMR (100 MHz, CDCI3): 6 149.6, 149.3, 137.9, 137.9, 136.9, 136.9, 129.3, 129.2, 128.8, 128.8, 127.0, 126.4, 126.2, 111.6, 110.9, 87.2, 87.0, 77.8, 76.6, 52.2, 51.1 , 39.8, 39.6, 20.3, 19.5;
UV (EtOH): Amax 466 nm.
Formaldehyde (0.137 mL, 4.0 eq., 1 .84 mmol) and formic acid (0.019 mL, 1.1 eq., 0.51 mmol) in 1 ,2-dichloroethane (9.2 mL, 0.05 M) were added to a solution of 1- ((2-bromo-4-(trifluoromethoxy)phenyl)amino)-3-(4-nitrophenyl)propan-2-ol (0.2 g, 1.0 eq., 0.46 mmol). The resulting mixture was stirred at room temperature for 2 days. The crude product was diluted with water (20 mL), and the aqueous layer was extracted using CH2CI2 (40 mL x 3). The combined organic layers were washed with water (20 mL), brine, dried over MgSC and concentrated under reduced pressure. The crude was purified by silica-gel column chromatography (pet. ether/EtOAc + 3% EtsN, PE 100-60:40-50:50-45:55-40:60-50:50, Rf. 0.54) to provide the title compound (0.45 g, 53%) as a sticky yellow oil.
IR: Vmax (film) 2924 (C-H, aromatic), 1516, 1343 (C-H, aromatic), 1248, 1213 (C-O-C), 1030 (C-Br);
1H N MR (400 MHz, CDCI3): 5 2.95-3.09 (2H, m), 3.21 -3.29 (1 H, m), 3.56- 3.63 (1 H, m), 4.27-4.36 (1 H, m), 4.87 (1 H, d, J = 5.8 Hz), 4.92 (1 H, d, J = 5.8 Hz), 7.02-7.08 (1 H, m), 7.08-7.12 (1 H, m), 7.39-7.47 (3H, m), 8.15 (1 H, d, J = 8.9 Hz);
13C NMR (100 MHz, CDCI3): 5 40.1 , 56.9, 76.1 , 84.0, 117.6, 119.2, 120.4, 120.9, 121.8, 126.9, 130.2, 144.5, 144.5, 145.7, 147.0; 19F{1H} NMR (470 MHz, CDCI3) 5 -58.6.
Formaldehyde (0.139 mL, 4.0 eq., 1 .88 mmol) and formic acid (0.020 mL, 1.1 eq., 0.52 mmol) in 1 ,2-dichloroethane (9.4 mL, 0.05 M) were added to a solution of 1 -
((6-bromo-2,3,4-trifluorophenyl)amino)-3-(4-nitrophenyl)propan-2-ol (0.19 g, 1.0 eq., 0.47 mmol). The resulting mixture was stirred at room temperature for 2 days. The crude product was diluted with water (20 mL), and the aqueous layer was extracted using CH2CI2 (40 mL x 3). The combined organic layers were washed with water (20 mL), brine, dried over MgSC and concentrated under reduced pressure. The crude was purified by silica-gel column chromatography (pet. ether/EtOAc + 3% EtsN, PE 100-60:40-50:50-45:55-40:60-50:50, Rf. 0.70) to provide the title compound (81.6 mg, 42%) as a colourless oil.
IR: Vmax (film) 1927 (C-H, aromatic ), 1501 (N-O, nitro), 1201-1179 (C-O-C), 1343 (C-F), 654 (C-Br);
1H NMR (400 MHz, CDCI3): 6 2.98-3.16 (2H, m), 3.18-3.22 (1 H, m), 3.57-3.64 (1 H, m), 4.38-4.47 (1 H, m), 4.71 -4.74 (1 H, m), 4.84-4.86 (1 H, m), 7.22-7.29 (1 H, m), 7.45 (1 H, d, J = 9.1 Hz), 8.16 (1 H, d, J = 9.1 Hz);
13C NMR (100 MHz, CDCI3): 6 39.9, 55.8, 84.1 , 93.2, 115.9, 116.0, 123.8,
130.3, 132.3, 138.6, 141.3, 145.9, 147.2; 19F{1H} NMR (470 MHz,CDCI3) 6 -149.7, -
161.3.
Formaldehyde (4 eq) and formic acid (1.1 eq.) in 1 ,2-dichloroethane (DCE) were added to a solution of amino alcohol (1 eq.). The resulting mixture was stirred under an N2 atmosphere at room temperature for 2 days. The crude product was diluted with water (5 mL), and the aqueous layer was extracted using DCM (3 x 5 mL). The combined organic layers were washed with brine (5 mL) and water (5 mL), dried over MgSC , and concentrated under reduce pressure. The crude product was pure based on 1H NMR analysis. The target compound was obtained as a sticky yellow oil (37.1 mg, 50%).
IR: Vmax = 3092 (C-H, alkene), 2921 (C-H, alkane), 1900 (C-H, aromatic), 1594 (N-O, nitro), 1303-1264 (C-O-C), 802 (C-CI);
1H NMR (400 MHz, CDCI3): 6 8.04 (m, 1 H), 7.98 (m, 2H), 7.42 (m, 2H), 7.32 (m, 2H), 5.55-5.24 (m, 2H), 4.48 (m, 1 H), 3.97-85 (m, 2H), 2.76 (m, 2H).
Claims
CLAIMS A method for synthesising a photolytical ly degradable compound, the method comprising: a) defining a biologically active compound which analogue is to be synthesised, wherein the biologically active compound comprises at least one aromatic group, the aromatic group being substituted, b) providing a reactant molecule comprising the at least one aromatic group, and c) synthesising a photolytically degradable compound by introducing in the reactant molecule at least one nitro substitution in said at least one aromatic group and introducing an oxazolidine group, wherein the photolytically degradable compound is defined by Formula I:
Formula I wherein at least one of A, B, C and D is selected from a group consisting of H, Cl, Br, B(OH)2, CN, CH2NR1 R2 and [CH2NR1R2R3]+, wherein each of R1, R2 and R3 is selected from a group consisting of H, branched or unbranched C-i-Ce alkyl, and O(CH2)o(CX2)p(CH2)q(CHX)r(CH2)s(CX2)t(CH2)u(CX3)v(CHX2)w(CH2X)x(C H3)y, where o = 0-5, p = 0-5, q = 0-5, r = 0-5, s = 0-4, t = 0-4, u = 0-4, v = 0-1 , w = 0-1 , x = 0-1 , y = 0-1 , provided that only one of v, w, x and y is 1 , while the other three of v, w, x and y are 0, and where X is selected from a group consisting of F and Cl, while each of the other three of A, B, C and D is
1 ) independently selected from a group consisting of H, F, Cl, I, Br, CN, CF3, CI-C6 alkyl, alkoxy with a Ci-C6 alkyl, NH2, NHR1, NR1R2 and [NR1R2R3]+, where R1, R2 and R3 are as defined above, and
2) is attached to any carbon atom available for substitution in the phenyl group, n is 0-4,
Z is one selected from a group consisting of H, aryl, and NHC(O)R7, wherein
R7 is selected from a group consisting of R5, wherein R5 is branched or unbranched C1-C3 alkyl,
and derivatives thereof comprising one or more selected from a group consisting of F and Cl, and wherein
K is same as L, wherein L is selected from a group consisting of H, branched or unbranched C1 -C6 alkyl, alkene and (CH2)o(CX2)p(CH2)q(CHX)r(CH2)s(CX2)t(CH2)u(CX3)v(CHX2)w(CH2X)x(CH3 )y, wherein o = 0-5, p = 0-5, q = 0-5, r = 0-5, s = 0-4, t = 0-4, u = 0-4, v = 0-1 , w = 0-1 , x = 0-1 , y = 0-1 , provided that only one of v, w, x, and y is 1 , while each of the other three of v, w, x, and y is 0, and wherein X is at least one selected from a group consisting of F, Cl, alkyne and
K is H and L is as defined above, or
K is H and L is CH2OR4, wherein R4 is selected from a group consisting of H and branched or unbranched C-i-Ce alkyl,
2. The method according to claim 1 , wherein Z is aryl as defined by Formula II:
Formula II wherein each of E, F, G and H is as defined for A, B, C and D in claim 1 . The method according to claim 2, wherein the nitro group is in meta-, ortho- or para-position to the carbon attaching Z to the carbon chain of the photolytically degradable compound defined by Formula I. The method according to claim 1 , wherein A, B, C, D, L, K and H are same and Z
The method according to any one of the preceding claims, wherein K is same as L, wherein L is one selected from a group consisting of branched or unbranched C-i-Ce alkyl, branched or unbranched C1-C3 alkyl, and C1-C2 alkyl. The method according to any one of the preceding claims, wherein K is H and L is selected from a group consisting of CH2CH2OR and CH2CH2CH2OR, wherein R is selected from a group consisting of H, and branched or unbranched C-i-Ce alkyl.
The method according to claim 1 , wherein Q is H and K is The method according to claim 1 , wherein said photolytically degradable compound is a chloramphenicol analogue as depicted by Formula VI A.
Formula VI A The method according to claim 1 , wherein said photolytically degradable compound is a chloramphenicol analogue defined by Formula VI B, wherein n = 0-4.
Formula VI B The method according to claim 9, wherein said photolytically degradable compound is a chloramphenicol analogue according to Formula VI B, wherein one or more Cl is substituted with F. A photolytically degradable compound obtained according to claim 1 , wherein said photolytically degradable compound is any one of chloramphenicol analogues depicted by Formula VI C, wherein n = 0 or 1.
Chloramphenicol analogues
Formula VI C A photolytically degradable compound obtained according to claim 1 , wherein the photolytically degradable compound is as defined by Formula VII.
Formula VII
Formula
13. The method according to any one of the preceding claims, wherein at least one benzylic C-C bond of said photolytically degradable compound is heterolytically cleaved by exposure to light at basic pH in aqueous environment.
14. The method according to claim 13, wherein said basic pH is between about 7 and about 11 .
15. The method according to claim 13, wherein said basic pH is between about 7 and about 8.
16. The method according to any one of the preceding claims, wherein the biologically active compound which analogue is to be synthesised has at least one activity selected from a group consisting of an antimicrobial activity and a pesticidal activity.
17. The method according to any one of the preceding claims, wherein the biologically active compound which analogue is to be synthesised is an antibiotic selected from a group consisting of ciprofloxacin, chloramphenicol and penicillin.
18. The method according to any one of the preceding claims, wherein the biologically active compound which analogue is to be synthesised is a pesticide selected from the group consisting of diflubenzuron, teflubenzuron and lufenuron.
19. A method for managing water resources by utilising the photolytically degradable compounds of any one of the preceding claims in treatment of water, the water containing at least one selected from a group consisting of microorganisms and pests.
20. The photolytically degradable compound of any one of the preceding claims for use in at least reducing or controlling the size of a population of salmon lice (Lepeophtheirus salmonis).
21 . The photolytically degradable compound of any one of the preceding claims for use in at least diminishing direct or indirect damage salmon lice causes to fish.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE2251209-9 | 2022-10-14 | ||
SE2251209 | 2022-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024079276A1 true WO2024079276A1 (en) | 2024-04-18 |
Family
ID=88413370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/078379 WO2024079276A1 (en) | 2022-10-14 | 2023-10-12 | Photolytically degradable compounds and methods for synthesising thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024079276A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002068427A1 (en) * | 2001-02-23 | 2002-09-06 | Ligand Pharmaceuticals Incorporated | Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds |
EP3135669A1 (en) * | 2014-04-24 | 2017-03-01 | Dong-A ST Co., Ltd. | Oxazolidine-based compound and selective androgen receptor agonist comprising same |
CA2972079A1 (en) | 2017-06-26 | 2018-12-26 | Arumugam Jayaraman | A potent synthetic inorganic antibacterial with activity against drug-resistant pathogens |
-
2023
- 2023-10-12 WO PCT/EP2023/078379 patent/WO2024079276A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002068427A1 (en) * | 2001-02-23 | 2002-09-06 | Ligand Pharmaceuticals Incorporated | Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds |
EP3135669A1 (en) * | 2014-04-24 | 2017-03-01 | Dong-A ST Co., Ltd. | Oxazolidine-based compound and selective androgen receptor agonist comprising same |
CA2972079A1 (en) | 2017-06-26 | 2018-12-26 | Arumugam Jayaraman | A potent synthetic inorganic antibacterial with activity against drug-resistant pathogens |
Non-Patent Citations (5)
Title |
---|
BJORØY NOREVIK LENE ET AL: "Synthesis and photodecomposition of antibiotics containing ethanolamine and oxazolidine moieties", FACULTY OF SCIENCE AND TECHNOLOGY BACHELOR'S THESIS, 15 May 2023 (2023-05-15), pages 1 - 41, XP093107109, Retrieved from the Internet <URL:https://uis.brage.unit.no/uis-xmlui/handle/11250/3074424?show=full> [retrieved on 20231129] * |
HAMRE, PARASITOL. INT., vol. 58, 2009, pages 451 - 460 |
KOTHA, S.BEHERA, MSHAH, V., A. SYNLETT, vol. 12, 2005, pages 1877 - 1880 |
L.N. ZORINA: "New approaches to synthesis of N-aryl-1,3-oxazolidines and N-aryl 1,3-tetrahydrooxazines", DOKLADY AKADEMII NAUK SSSR, 308(5), 1150-4 CHEM., 1989, vol. 308, no. 5, 1 January 1989 (1989-01-01), XP093107301 * |
TIMM ALEXANDER ET AL: "Photolysis of four [beta]-lactam antibiotics under simulated environmental conditions: Degradation, transformation products and antibacterial activity", SCIENCE OF THE TOTAL ENVIRONMENT, ELSEVIER, AMSTERDAM, NL, vol. 651, 20 September 2018 (2018-09-20), pages 1605 - 1612, XP085508518, ISSN: 0048-9697, DOI: 10.1016/J.SCITOTENV.2018.09.248 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1178039B1 (en) | Derivatives of phenyl(thio)urea and phenyl(thio)carbamate fungicides | |
Abdelrazek et al. | Synthesis and Molluscicidal Activity of Some 1, 3, 4‐Triaryl‐5‐chloropyrazole, Pyrano [2, 3‐c] pyrazole, Pyrazolylphthalazine and Pyrano [2, 3‐d] thiazole Derivatives | |
Nadeem et al. | Synthesis and in vitro biological activities of 4, 5-disubstituted 1, 2, 4-triazole-3-thiols | |
Cunha et al. | Synthesis and antibacterial evaluation of 3, 5-diaryl-1, 2, 4-oxadiazole derivatives | |
Abdel-Raheem et al. | Some oxoimidazolidine and cyanoguanidine compounds: Toxicological efficacy and structure-activity relationships studies | |
JPS63287764A (en) | N-3-cyanobenzyl-heterocyclic compound and insecticide | |
WO2024079276A1 (en) | Photolytically degradable compounds and methods for synthesising thereof | |
DE2801868C2 (en) | Benzthiazolone and benzoxazolone derivatives | |
JPS63267752A (en) | Insecticidal n-(optionally substituted)-n'- substituted-n,n'-disubstituted hydrazine | |
Gholivand et al. | Phosphorhydrazide inhibitors: toxicological profile and antimicrobial evaluation assay, molecular modeling and QSAR study | |
WO2022223390A1 (en) | Photolytically degradable compounds and methods | |
Nurkenov et al. | Synthesis of new hydrazones based on o-and p-hydroxybenzohydrazides. | |
CN109666003B (en) | Pyrazinamide compound containing iodine element, preparation method and application thereof, and bactericide | |
Belakhov et al. | Preparation and Insecticidal Activity of Organosulfur Derivatives of β-D-Ribofuranoside | |
US4069319A (en) | Novel thiadiazoles | |
CN101402606A (en) | Nitrogen heterocyclic ring substituted arylpropenone compounds, preparation method and application thereof | |
CN109096209B (en) | Pyrazinamide compounds, preparation method and application thereof, and bactericide | |
RU2783242C1 (en) | 4-[(4-bromophenyl)((4-nitrophenyl)amino)methylidene]-5-hydroxy-5-(trichloromethyl)dihydrofuran-2,3-dione with antimicrobial activity | |
JPH06340643A (en) | Oxazole or thiazole derivative, its production and herbicide | |
CN1247548C (en) | Cesium triazoleamide compounds and their preparation and use | |
Samita et al. | An Efficacious Protocol for the Reduction of Benzothiazole Using Mg/MeOH and Their Antinemic Activity against Meloidogyne incognita | |
RU2009141C1 (en) | 4-acetyl-3-benzyl-2-methylthioimidazo (4,5 ) indole protecting liver against poisoning of carbon tetrachloride | |
SU1456010A3 (en) | Method of producing nitrogen-containing heterocyclic compounds | |
RU2039048C1 (en) | Trans-4-azido-3,6-dimethylhexahydropyrimidin-2-thione having nematocidal activity | |
CN103664823B (en) | Arylamine replaces 1,2,3,4 thiatriazole derivatives, Preparation Method And The Use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23789953 Country of ref document: EP Kind code of ref document: A1 |